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Abstract
Upper urinary tract transitional cell carcinoma (UUT-TCC) is quite an uncommon disease, and its prognosis differs
among individuals irrespective of tumor stage. DNA repair gene polymorphisms are reported to result in the mod-
ulation of the repair capacity and might influence the prognosis of UUT-TCC. We examined the associations be-
tween functional polymorphisms in five DNA repair genes, and the prognosis of UUT-TCC in 103 UUT-TCC
patients. Variant alleles in xeroderma pigmentosum complementation group C, more than three total variant alleles
in all DNA repair genes studied and more than two total variant alleles in three nucleotide excision repair genes
were independently associated with improved overall and disease-specific survival of UUT-TCC patients in multi-
variate analysis (P = .0063 and P = .0005 for xeroderma pigmentosum complementation group C, P = .016 and
P = .0016 for all genes, and P = .0053 and P = .018 for nucleotide excision repair genes, respectively). These
results suggest that some DNA repair gene polymorphisms may preoperatively be valuable as prognostic factors
for UUT-TCC beyond tumor stage and grade, helping to provide optimal treatment strategies for individual patients.
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Introduction
Upper urinary tract transitional cell carcinoma (UUT-TCC), which
arises from the renal pelvis or ureter, is quite an uncommon disease,
accounting for only 5% of all cases of urothelial carcinoma [1]. Al-
though the standard treatment for localized UUT-TCC is surgical
resection, local recurrence or distant metastasis sometimes occurs
during the follow-up after surgery, and the survival rate at 5 years
is less than 50% for patients with T2–T3 tumors [1]. Therefore,
some patients with localized UUT-TCC need combined-modality
therapy, chemotherapy, and/or radiotherapy and nephroureterectomy
[2,3]. Meanwhile, systemic chemotherapy is offered as a viable ther-
apeutic option for patients with metastatic disease at the time of ini-
tial diagnosis. The survival rate at 5 years is normally less than 10%
for patients with T4 or N+/M+ tumors [1]; however, some of these
patients have a response to therapy and a relatively long-term survival
[4]. It is therefore acknowledged that the prognosis of UUT-TCC
differs among individuals irrespective of tumor stage. Thus, although
tumor stage and grade have been considered the main prognostic fac-
tors for UUT-TCC [1,5], more accurate prognostic markers may
help to provide optimal treatment strategies for individual patients.
The complex system of DNA repair enzymes plays a vital role in
protecting the genome from the consequences of exogenous and en-
dogenous mutagenic exposure [6]. There are at least four known
pathways of DNA repair, namely, base excision repair, nucleotide ex-
cision repair (NER), double-strand break (including homologous re-
combination and nonhomologous end-joining) repair, and mismatch
repair, each of which operates on a specific type of damaged DNA
and each of which involves numerous molecules [7]. Any decreased
repair capacity of these enzymes causes alterations to the genome
and subsequent cancer development [6]. There are several common
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polymorphisms in genes encoding DNA repair enzymes, and some of
these polymorphisms are reported to result in subtle structural altera-
tions in the repair enzyme and modulation of its repair capacity. The
wild-type and variant genotypes of xeroderma pigmentosum comple-
mentation groups C (XPC ), D (XPD), and G (XPG ) and X-ray repair
cross-complementing groups 1 (XRCC1) and 3 (XRCC3) have been
shown to be associated with different levels of DNA repair activity
using various assays [8–13]. In this manner, these polymorphisms
may contribute to interindividual cancer susceptibility in the general
population. The associations between DNA repair gene polymor-
phisms and bladder cancer risk or prognosis have been demonstrated
in several reports [7,14–20]. However, a study on the association of
these polymorphisms with UUT-TCC is lacking.
Risk factors for UUT-TCC include cigarette smoking and expo-
sure to certain industrial dyes or solvents [21], and some of the
DNA damage that may occur as a result of these factors would be
repaired by the DNA repair enzymes. The accumulation of multiple
genetic changes is considered to cause the development and progres-
sion of UUT-TCC, such as bladder TCC [22–24]. We previously
reported associations between DNA repair gene polymorphisms
and tumor stage, grade, p53 alteration, or prognosis in patients with
bladder cancer [17,18,25]. These polymorphisms, as host genetic fac-
tors, may also influence the progression and prognosis of UUT-TCC
due to the accumulation of multiple genetic changes caused by the
modulated DNA repair capacity. In the current study, we investi-
gated the associations between polymorphisms in the DNA repair
genes, XPC (Lys939Gln, A/C), XPD (Lys751Gln, A/C), and XPG
(Asp1104His, G/C) (involved in NER), XRCC1 (Arg399Gln, G/A)
(involved in base excision repair), and XRCC3 (Thr241Met, C/T)
(involved in double-strand break repair), and clinicopathologic param-
eters and survival in patients with UUT-TCC to determine the value
of these polymorphisms as prognostic markers. Germline genetic poly-
morphisms are thought to be suitable markers for UUT-TCC patients,
because polymorphisms are available without operation. The poly-
morphisms studied in this report were generally selected according
to prior data on functional effects or reports of association with malig-
nancies, to increase the likelihood of positive findings [7,12,26], and
we have consecutively investigated the effects of these polymorphisms
on cancer biology [16–18,25,27]. In addition, we also examined the
association of these polymorphisms with susceptibility to UUT-TCC
in the present report, using the case–control study. To our knowledge,
there have been few case–control studies on genetic polymorphisms,
limited to UUT-TCC, to date.
Materials and Methods
Patients and Control Subjects
The study group comprised 103 patients (69 men and 34 women;
median age, 70 years; age range, 44 to 93 years) with histopatholog-
ically confirmed UUT-TCC at Yamaguchi University Hospital, Ube,
Japan, between August 1990 and June 2006. As control subjects,
215 healthy volunteers were chosen from the same geographical area
(148 men and 67 women; median age, 67 years; age range, 29 to
87 years), as previously reported [27]. This study was approved by
the institutional ethical committee at the Graduate School of Medi-
cine, Yamaguchi University, and written informed consent was ob-
tained from each patient and control. The characteristics of the
UUT-TCC patients and control subjects, all of whom were native Jap-
anese, are shown in Table 1. Regarding control subjects, only age and
gender were recorded as personal data. The tumor staging system was
based on the American Joint Commission on Cancer staging system
[28], and the tumors were histopathologically graded according to the
World Health Organization’s classification. Of the 103 patients with
UUT-TCC, 97 underwent an operation that was normally nephro-
ureterectomy with removal of the bladder cuff. Platinum-based chemo-
therapy, radiotherapy, or both were performed in 24, 4, or 16 patients,
respectively. Follow-up information was available for 100 of 103 pa-
tients with UUT-TCC. Of these, at a median follow-up of 36 months
(mean, 44.5 months; range, 2 to 167 months), 39 and 24 suffered
death from any cause and disease-specific death during the follow-
up, respectively.
DNA Extraction and Genotyping
Peripheral blood samples were collected from each patient at initial
diagnosis and from each control subject, and lymphocyte DNA was
extracted using the QIAamp DNA Mini Kit (VWR International,
West Chester, PA). Polymorphisms in XPC, XPD, XPG, XRCC1,
and XRCC3 genes were genotyped using polymerase chain reaction
(PCR)–restriction fragment length polymorphism. This method, in-
cluding the primer sequences, PCR conditions, and restriction endo-
nucleases for each polymorphism, has been described previously
[12,16,18]. Briefly, the DNA fragments were amplified from 10 ng
Table 1. Clinicopathologic Characteristics of UUT-TCC Patients and Control Subjects.
Cases, n (%) Controls, n (%) P
Age, years Median (range) 70 (44-93) 67 (29-87)
< 70 48 (46.6) 122 (56.7)
≥ 70 55 (53.4) 93 (43.3) .090*
Gender Male 69 (67.0) 148 (68.8)
Female 34 (33.0) 67 (31.2) .74*
Smoking history No 41 (39.8)
Yes 54 (52.4)
Unknown 8 (7.8)
Tumor location Renal pelvis 40 (38.8)
Ureter 54 (52.4)
Both 9 (8.7)
Tumor stage Tis 9 (8.7)
Ta 5 (4.9)
T1 27 (26.2)
T2 18 (17.5)
T3 34 (33.0)
T4 5 (4.9)
TX 5 (4.9)
Lymph node metastasis Negative 83 (80.6)
Positive 10 (9.7)
Unknown 10 (9.7)
Distant metastasis Negative 89 (86.4)
Positive 5 (4.9)
Unknown 9 (8.7)
Tumor grade G1 3 (2.9)
G2 48 (46.6)
G3 47 (45.6)
GX 5 (4.9)
Histopathology Pure TCC 98 (95.1)
TCC with SCC 5 (4.9)
Operation Yes 97 (94.2)
No 6 (5.8)
Chemotherapy/radiotherapy None 55 (53.4)
Chemotherapy 24 (23.3)
Radiotherapy 4 (3.9)
Both 16 (15.5)
Unknown 4 (3.9)
UUT-TCC indicates upper urinary tract transitional cell carcinoma; SCC, squamous cell carcinoma.
*Difference between cases and controls (chi-square analysis).
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of DNA in 10 μl of PCR reactions containing 1.5 mM MgCl2,
0.2 mM each deoxyribonucleotide triphosphate, 0.3 U of AmpliTaq
Gold DNA polymerase (Applied Biosystems, Foster City, CA), and
0.3 μM each primer. The PCR products were digested with the ap-
propriate restriction endonucleases that recognized and cut either
wild-type or variant sequences at 37°C for at least 3 hours. The
digested PCR products were electrophoresed on 2% agarose gels
and were stained with ethidium bromide for visualization under
ultraviolet light. To control the restriction digestion of the PCR prod-
ucts, genotyping assays were randomly repeated and results were
checked for concordance. About 10% of the amplified fragments
were also randomly checked by direct DNA sequencing and compar-
ison of the PCR–restriction fragment length polymorphism and se-
quencing results showed 100% concordance in all experiments.
Variant alleles were defined as Gln for XPC, Gln for XPD, His for
XPG, Gln for XRCC1, and Met for XRCC3, according to previous
reports [12,16].
Statistical Analysis
Differences in the genotype and allele frequencies of the DNA
repair genes between the UUT-TCC cases and the control subjects,
and associations between the genotypes and the clinicopathologic
characteristics at the time of initial diagnosis of the UUT-TCC
patients, were assessed for statistical significance using the chi-square
analysis or two-sided Fisher’s exact test; odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated. P values less than .005
were considered to indicate statistical significance, because multiple
comparisons were conducted [29]. Overall and disease-specific sur-
vival of the UUT-TCC patients were calculated from the day of
initial diagnosis until the last follow-up or death from any cause
and from UUT-TCC, respectively; patients who were alive at the
last follow-up were censored at that time. The associations between
categorical variables, including DNA repair genotypes, and survival
were estimated by calculating the hazard ratios (HRs) with 95%
CIs using Cox proportional hazard regression models. In addition,
overall and disease-specific survival was analyzed by plotting Kaplan-
Meier curves, and the survival probability distributions were compared
using the log-rank test. Because the prognosis of cancer patients likely
involves multistep, multigenic pathways, it is unlikely that any one
single genetic polymorphism would have a dramatic effect on clinical
outcome, and it is important to undertake a pathway-based analysis of
multiple polymorphic genes [19]. Thus, we also analyzed the numbers
of total variant alleles in all DNA repair genes studied and in NER
genes (XPC, XPD, and XPG). P values less than .05 were considered
to indicate statistical significance in these tests and variables with P <
.05 in univariate analysis were also assessed for their relationship with
survival by multivariate analysis. Data were processed using JMP soft-
ware (SAS Institute Inc., Cary, NC).
Results
Genotype and Allele Frequencies of the DNA Repair Genes in
UUT-TCC Cases and Control Subjects
The genotype frequencies of the XPC, XPD, XPG, XRCC1, and
XRCC3 genes, in both the 103 UUT-TCC cases and the 215 control
subjects, were found to be in Hardy-Weinberg equilibrium. The
genotype and allele frequencies in cases and controls are shown in
Table 2. The Lys/Gln + Gln/Gln genotypes of the XPD gene were
less frequent in cases than in controls (OR: 0.26, 95% CI: 0.061-
0.77, P = .032; OR adjusted for age and gender: 0.29, 95% CI:
0.067-0.89, P = .053; two-sided Fisher’s exact test). The Gln alleles
of the XPD gene were also less frequent in cases than in controls
(OR: 0.24, 95% CI: 0.072-0.80, P = .013; two-sided Fisher’s exact
test). However, these differences were not statistically significant
when considering multiple comparisons (see Materials and Methods
section). No significant differences in genotype or allele frequencies,
between cases and controls, were observed for the other polymor-
phisms in the XPC, XPG, XRCC1, or XRCC3 genes.
Association Between DNA Repair Genotypes and Age, Gender,
Tumor Stage, and Grade in UUT-TCC Patients
The associations between DNA repair genotypes and age, gen-
der, tumor stage, and grade, in UUT-TCC patients, are presented
in Table 3. His/His genotypes of the XPG gene were more frequent
than Asp/Asp (OR: 4.5, 95% CI: 1.1-18, P = .038) or Asp/Asp +
Asp/His (OR: 2.4, 95% CI: 1.0-5.8, P = .045) genotypes in female
patients with UUT-TCC. In addition, Gln/Gln genotypes of the
XPC gene were less frequent than Lys/Lys (OR: 0.23, 95% CI:
0.066-0.83, P = .032) or Lys/Lys + Lys/Gln (OR: 0.30, 95% CI:
0.10-0.91, P = .028) genotypes in patients with T2/T3/T4 tumors.
However, these associations were not statistically significant. There
were no significant associations between DNA repair genotypes and
patient age or tumor grade.
Univariate Analysis of DNA Repair Genotypes and Overall
Survival of UUT-TCC Patients
A univariate Cox regression analysis for predicting the overall sur-
vival of UUT-TCC patients is presented in Table 4. XPC and XPG
genotypes, and the numbers of total variant alleles in all DNA repair
genes studied and in NER genes, were associated with the probability
of overall survival in UUT-TCC patients. Patients with Gln/Gln or
Lys/Gln + Gln/Gln genotypes of the XPC gene had significantly im-
proved overall survival compared with those with Lys/Lys genotypes
(HR: 0.48, 95% CI: 0.25-0.80, P = .0041 for Gln/Gln; HR: 0.60,
95% CI: 0.43-0.84, P = .0032 for Lys/Gln + Gln/Gln). In addition,
patients with more than two variant alleles in NER genes had signif-
icantly improved overall survival compared with those with two or
less variant alleles (HR: 0.45, 95% CI: 0.22-0.76, P = .0011). Over-
all survival was plotted for the Lys/Gln + Gln/Gln genotypes of the
XPC gene, His/His genotypes of the XPG gene, more than three var-
iant alleles in all DNA repair genes and more than two variant alleles
in NER genes, compared with the remaining groups, using Kaplan-
Meier survival curves (Figure 1, A–D, respectively). These genotypes
were associated with improved overall survival (P = .0016 for the
XPC gene, P = .016 for the XPG gene, P = .019 for the total variant
alleles in all DNA repair genes, and P = .0035 for the total variant
alleles in NER genes; log-rank test). Clinicopathologic variables were
also assessed for their relationship with the overall survival of UUT-
TCC patients by univariate analysis (Table 4). Tumor stage (T2/T3/
T4), distant metastasis and grade (G3) were associated with an un-
favorable outcome.
Multivariate Analysis of DNA Repair Genotypes and Overall
Survival of UUT-TCC Patients
Using multivariate analysis (model one) including all factors with
P < .05 in univariate analysis (tumor stage, distant metastasis, grade,
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and XPC and XPG genotypes), XPC genotypes (HR: 0.59, 95% CI:
0.40-0.86, P = .0063), as well as distant metastasis and grade, were
independently associated with overall survival (Table 4). When the
number of variant alleles in all DNA repair genes was used instead
of XPC and XPG genotypes (model two), the number of variant al-
leles (HR: 0.61, 95% CI: 0.37-0.92, P = .016), as well as distant
metastasis, was independently associated with overall survival. When
the number of variant alleles in NER genes was used instead of XPC
and XPG genotypes (model three), patients with more than two var-
iant alleles were independently associated with a favorable clinical
outcome (HR: 0.49, 95% CI: 0.24-0.83, P = .0053).
Univariate Analysis of DNA Repair Genotypes and
Disease-Specific Survival of UUT-TCC Patients
A univariate Cox regression analysis for predicting the disease-
specific survival of UUT-TCC patients is presented in Table 5. XPC
genotypes, and the numbers of total variant alleles in all DNA repair
genes and in NER genes, were significantly associated with the prob-
ability of disease-specific survival in UUT-TCC patients. Patients
with Gln/Gln genotypes of the XPC gene had significantly improved
disease-specific survival compared with those with Lys/Lys genotypes
(HR: 0.32, 95% CI: 0.076-0.74, P = .0039). In addition, patients
with more than three variant alleles in all DNA repair genes had sig-
nificantly improved disease-specific survival compared with those
with three or less variant alleles (HR: 0.43, 95% CI: 0.17-0.80,
P = .0048), and patients with more than two variant alleles in
NER genes also had significantly improved disease-specific survival
compared with those with two or less variant alleles (HR: 0.32,
95% CI: 0.076-0.70, P = .0015). Disease-specific survival was plot-
ted for the Lys/Gln + Gln/Gln genotypes of the XPC gene, His/His
genotypes of the XPG gene, more than three variant alleles in all
DNA repair genes and more than two variant alleles in NER genes,
compared with the remaining groups, using Kaplan-Meier survival
curves (Figure 2, A–D, respectively). These genotypes were associated
with improved disease-specific survival, except for XPG gene (P =
.0032 for the XPC gene, P = .069 for the XPG gene, P = .012 for
the total variant alleles in all DNA repair genes, and P = .0066 for the
total variant alleles in NER genes; log-rank test). Clinicopathologic
Table 2. Genotype and Allele Frequencies of DNA Repair Genes in UUT-TCC Cases and Controls.
Gene (polymorphism) Genotype or allele Cases, n (%) Controls, n (%) Crude Adjusted*
OR (95% CI) P† OR (95% CI) P†
XPC (Lys939Gln, A/C) Lys/Lys 30 (31.9) 70 (32.6) Ref. Ref.
Lys/Gln 46 (48.9) 114 (53.0) 0.94 (0.55-1.6) .83 1.0 (0.57-1.8) .97
Gln/Gln 18 (19.1) 31 (14.4) 1.4 (0.65-2.8) .41 1.4 (0.66-2.9) .38
Lys/Gln + Gln/Gln 64 (68.1) 145 (67.4) 1.0 (0.62-1.7) .91 1.1 (0.64-1.9) .75
Lys/Lys + Lys/Gln 76 (80.9) 184 (85.6) Ref. Ref.
Gln/Gln 18 (19.1) 31 (14.4) 1.4 (0.73-2.6) .30 1.4 (0.71-2.7) .33
Lys allele 106 (56.4) 254 (59.1) Ref.
Gln allele 82 (43.6) 176 (40.9) 1.1 (0.79-1.6) .53
XPD (Lys751Gln, A/C) Lys/Lys 96 (97.0) 192 (89.3) Ref. Ref.
Lys/Gln 3 (3.0) 20 (9.3) 0.30 (0.070-0.90) .057 0.33 (0.074-1.0) .082
Gln/Gln 0 (0.0) 3 (1.4) Not calculated .83 Not calculated .84
Lys/Gln + Gln/Gln 3 (3.0) 23 (10.7) 0.26 (0.061-0.77) .032 0.29 (0.067-0.89) .053
Lys/Lys + Lys/Gln 99 (100.0) 212 (98.6) Ref. Ref.
Gln/Gln 0 (0.0) 3 (1.4) Not calculated .83 Not calculated .84
Lys allele 195 (98.5) 404 (94.0) Ref.
Gln allele 3 (1.5) 26 (6.0) 0.24 (0.072-0.80) .013
XPG (Asp1104His, G/C) Asp/Asp 19 (19.6) 51 (23.7) Ref. Ref.
Asp/His 43 (44.3) 99 (46.0) 1.2 (0.62-2.2) .64 1.1 (0.56-2.2) .80
His/His 35 (36.1) 65 (30.2) 1.4 (0.75-2.9) .28 1.2 (0.60-2.4) .61
Asp/His + His/His 78 (80.4) 164 (76.3) 1.3 (0.72-2.4) .42 1.1 (0.61-2.1) .74
Asp/Asp + Asp/His 62 (63.9) 150 (69.8) Ref. Ref.
His/His 35 (36.1) 65 (30.2) 1.3 (0.78-2.2) .31 1.2 (0.74-2.1) .41
Asp allele 81 (41.8) 201 (46.7) Ref.
His allele 113 (58.2) 229 (53.3) 1.2 (0.87-1.7) .25
XRCC1 (Arg399Gln, G/A) Arg/Arg 52 (52.5) 120 (55.8) Ref. Ref.
Arg/Gln 39 (39.4) 85 (39.5) 1.1 (0.64-1.7) .82 1.0 (0.60-1.7) > 0.99
Gln/Gln 8 (8.1) 10 (4.7) 1.8 (0.67-4.9) .22 2.0 (0.72-5.6) .17
Arg/Gln + Gln/Gln 47 (47.5) 95 (44.2) 1.1 (0.71-1.8) .59 1.1 (0.67-1.8) .70
Arg/Arg + Arg/Gln 91 (91.9) 205 (95.3) Ref. Ref.
Gln/Gln 8 (8.1) 10 (4.7) 1.8 (0.67-4.7) .23 2.0 (0.73-5.4) .17
Arg allele 143 (72.2) 325 (75.6) Ref.
Gln allele 55 (27.8) 105 (24.4) 1.2 (0.81-1.7) .37
XRCC3 (Thr241Met, C/T) Thr/Thr 82 (84.5) 173 (82.0) Ref. Ref.
Thr/Met 15 (15.5) 33 (15.6) 0.96 (0.48-1.8) .90 1.0 (0.50-2.0) .98
Met/Met 0 (0.0) 5 (2.4) Not calculated .85 Not calculated .85
Thr/Met + Met/Met 15 (15.5) 38 (18.0) 0.83 (0.42-1.6) .58 0.89 (0.45-1.7) .74
Thr/Thr + Thr/Met 97 (100.0) 206 (97.6) Ref. Ref.
Met/Met 0 (0.0) 5 (2.4) Not calculated .85 Not calculated .85
Thr allele 179 (92.3) 379 (89.8) Ref.
Met allele 15 (7.7) 43 (10.2) 0.74 (0.40-1.4) .33
UUT-TCC indicates upper urinary tract transitional cell carcinoma; OR, odds ratio; CI, confidence interval; Ref., Reference.
*Adjusted for age and gender.
†Chi-square analysis or two-sided Fisher’s exact test.
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variables were also assessed for their relationship with the disease-
specific survival of UUT-TCC patients by univariate analysis (Table 5).
Tumor stage (T2/T3/T4), lymph node metastasis, distant metastasis,
and grade (G3) were associated with an unfavorable outcome.
Multivariate Analysis of DNA Repair Genotypes and
Disease-Specific Survival of UUT-TCC Patients
Using multivariate analysis (model one) including all factors with
P < .05 in univariate analysis (tumor stage, lymph node metastasis,
Table 4. Univariate and Multivariate Cox Regression Analyses for Predicting Overall Survival of UUT-TCC Patients.
Variable (n) Deaths, n Univariate Analysis Multivariate Model One Multivariate Model Two Multivariate Model Three
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age
< 70 (46) 17 Ref.
≥ 70 (54) 22 1.3 (0.92-1.8) .15
Gender
Men (68) 28 Ref.
Women (32) 11 0.98 (0.68-1.4) .93
Tumor location
Renal pelvis (40) 15 Ref.
Ureter + Both (60) 24 0.95 (0.69-1.3) .77
Tumor stage
Tis/Ta/T1 (39) 12 Ref. Ref. Ref. Ref.
T2/T3/T4 (56) 25 1.6 (1.1-2.4) .0061 1.4 (0.93-2.1) .12 1.3 (0.90-1.9) .17 1.4 (0.94-2.0) .11
Lymph node metastasis
Negative (80) 30 Ref.
Positive (10) 5 1.5 (0.87-2.3) .13
Distant metastasis
Negative (86) 32 Ref. Ref. Ref. Ref.
Positive (5) 4 2.3 (1.2-3.8) .012 2.2 (1.1-4.0) .022 2.1 (1.1-3.6) .026 1.8 (0.95-3.1) .067
Tumor grade
G1/G2 (48) 13 Ref. Ref. Ref. Ref.
G3 (47) 23 1.5 (1.1-2.2) .015 1.5 (1.0-2.2) .048 1.3 (0.94-1.9) .11 1.3 (0.88-1.9) .21
Histopathology
Pure TCC (95) 36 Ref.
TCC with SCC (5) 3 1.2 (0.59-2.0) .55
Operation
Yes (94) 37 Ref.
No (6) 2 1.2 (0.50-2.3) .58
Chemotherapy/Radiotherapy
None (52) 18 Ref.
Chemotherapy (24) 9 0.91 (0.59-1.3) .64
Radiotherapy (4) 2 1.1 (0.45-2.2) .73
Both (16) 7 1.2 (0.72-1.8) .53
XPC (Lys939Gln, A/C)
Lys/Lys (27) 17 Ref. Ref.
Lys/Gln (46) 15 0.65 (0.45-0.93) .019
Gln/Gln (18) 4 0.48 (0.25-0.80) .0041
Lys/Gln + Gln/Gln (64) 19 0.60 (0.43-0.84) .0032 0.59 (0.40-0.86) .0063
Lys/Lys + Lys/Gln (73) 32 Ref.
Gln/Gln (18) 4 0.61 (0.33-0.97) .035
XPD (Lys751Gln, A/C)*
Lys/Lys (93) 35 Ref.
Lys/Gln + Gln/Gln (3) 1 0.64 (0.15-1.5) .36
XPG (Asp1104His, G/C)
Asp/Asp (19) 7 Ref.
Asp/His (41) 23 1.3 (0.86-2.0) .22
His/His (34) 7 0.70 (0.40-1.2) .20
Asp/His + His/His (75) 30 1.0 (0.71-1.7) .82
Asp/Asp + Asp/His (60) 30 Ref. Ref.
His/His (34) 7 0.60 (0.37-0.89) .010 0.79 (0.48-1.2) .30
XRCC1 (Arg399Gln, G/A)*
Arg/Arg (50) 20 Ref.
Arg/Gln + Gln/Gln (46) 17 0.91 (0.65-1.3) .59
XRCC3 (Thr241Met, C/T)*
Thr/Thr (79) 31 Ref.
Thr/Met + Met/Met (15) 4 0.68 (0.37-1.1) .12
Total variant alleles in DNA repair genes
≤ 3 (73) 33 Ref. Ref.
> 3 (27) 6 0.60 (0.37-0.91) .013 0.61 (0.37-0.92) .016
Total variant alleles in NER genes†
≤ 2 (70) 36 Ref. Ref.
> 2 (29) 3 0.45 (0.22-0.76) .0011 0.49 (0.24-0.83) .0053
Bold font indicates statistical significance.
UUT-TCC indicates upper urinary tract transitional cell carcinoma; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; NER, nucleotide excision repair; Ref., Reference.
*For those polymorphisms with few homozygous variant alleles, only the combined results of the heterozygous and homozygous variant alleles were shown.
†NER genes included XPC, XPD, and XPG.
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distant metastasis, grade, and XPC genotypes), XPC genotypes (HR:
0.37, 95% CI: 0.19-0.65, P = .0005), as well as distant metastasis,
were independently associated with disease-specific survival (Table 5).
The XPC genotypes were the most powerful prognostic markers, fol-
lowed by distant metastasis (HR: 6.6, 95% CI: 1.7-22, P = .0069).
When the number of variant alleles in all DNA repair genes was used
instead of XPC genotypes (model two), the number of variant alleles
(HR: 0.31, 95% CI: 0.073-0.70, P = .0016), as well as distant metas-
tasis, was independently associated with disease-specific survival. When
the number of variant alleles in NER genes was used instead of XPC
genotypes (model three), the number of variant alleles (HR: 0.39,
95% CI: 0.090-0.87, P = .018), as well as tumor stage and distant
metastasis, was independently associated with disease-specific survival.
Discussion
In the present study, we found that some DNA repair genotypes
were independently associated with the overall or disease-specific
survival of UUT-TCC patients beyond tumor stage and grade. Re-
cently, there have been some reports that have assessed molec-
ular markers for their independent prognostic potential in patients
with UUT-TCC [5,30–32]. However, most of these series include
80 cases or less, and the power may be limited in the analyses.
In addition, almost all of the reported molecular markers need
tumor tissue samples obtained by operation and complex techniques
[5,30–32], unlike the evaluation of germline genetic polymorphisms,
which requires little more than a peripheral blood sample and stan-
dard PCRs, making these tests potentially useful in the clinical
setting [33]. In UUT-TCC, it is difficult to obtain enough tumor
tissue samples for the molecular analyses on biopsy. DNA repair geno-
types may therefore be preoperatively valuable as prognostic factors
for UUT-TCC.
Recently, Brown et al. [34] emphasized the importance of neo-
adjuvant chemotherapy as a first-line strategy for localized UUT-TCC
patients with a high risk of recurrence or metastasis, to improve the
outcome; however, they also mentioned the absence of a useful marker
for risk assessment. Patients with UUT-TCC often sustain a significant
loss of renal reserve as a result of nephroureterectomy, frequently in the
setting of advanced age or chronic renal insufficiency. This factor es-
sentially precludes the ability to deliver effective doses of cytotoxic
chemotherapy after surgery [4]. The DNA repair genotypes could
therefore be helpful in preoperative patient selection for neoadjuvant
chemotherapy for UUT-TCC. Predicting the prognosis of UUT-TCC
based on DNA repair genotypes might help to stratify the patients by
their risk of progression and to provide personalized treatments and
follow-up strategies.
In this study, some DNA repair gene polymorphisms potentially
influenced the malignant phenotypes of UUT-TCC. This result may
Figure 1. Kaplan-Meier overall survival curves for patients with UUT-TCC by DNA repair genotypes (log-rank tests). (A) Lys/Gln + Gln/Gln
versus Lys/Lys of XPC; P = .0016. (B) His/His versus Asp/Asp + Asp/His of XPG; P = .016. (C) Total variant alleles in all DNA repair genes
studied: > 3 versus ≤ 3; P = .019. (D) Total variant alleles in NER genes (XPC, XPD, and XPG): > 2 versus ≤ 2; P = .0035.
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be due to the modulated DNA repair capacity caused by the DNA
repair gene polymorphisms. Various assays have been developed to
quantify DNA repair activity for DNA repair gene polymorphisms,
including the Comet assay and the host cell reactivation assay [9,33].
Despite some inconsistencies in the literature, it seems likely that the
wild-type and variant genotypes are associated with different levels
of DNA repair activity [8–12]. Our patients with variant alleles in
the XPC gene, those with more than three total variant alleles in
Table 5. Univariate and Multivariate Cox Regression Analyses for Predicting Disease-Specific Survival of UUT-TCC Patients.
Variable (n) Deaths, n Univariate Analysis Multivariate Model One Multivariate Model Two Multivariate Model Three
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age
< 70 (46) 13 Ref.
≥ 70 (54) 11 0.97 (0.64-1.5) .87
Gender
Men (68) 18 Ref.
Women (32) 6 0.87 (0.52-1.3) .54
Tumor location
Renal pelvis (40) 8 Ref.
Ureter + both (60) 16 1.0 (0.67-1.6) .93
Tumor stage
Tis/Ta/T1 (39) 4 Ref. Ref. Ref. Ref.
T2/T3/T4 (56) 18 2.3 (1.4-4.2) .0008 1.8 (0.98-4.1) .060 1.7 (0.98-3.5) .058 1.8 (1.0-3.5) .033
Lymph node metastasis
Negative (80) 16 Ref. Ref. Ref. Ref.
Positive (10) 5 2.0 (1.2-3.3) .016 0.66 (0.20-2.6) .52 0.76 (0.34-1.5) .46 0.71 (0.30-1.5) .38
Distant metastasis
Negative (86) 18 Ref. Ref. Ref. Ref.
Positive (5) 4 3.0 (1.6-5.3) .0022 6.6 (1.7-22) .0069 3.4 (1.5-7.4) .0034 2.9 (1.3-6.5) .012
Tumor grade
G1/G2 (48) 6 Ref. Ref. Ref. Ref.
G3 (47) 15 1.7 (1.1-2.9) .018 1.5 (0.86-3.0) .16 1.5 (0.88-2.6) .14 1.4 (0.82-2.5) .22
Histopathology
Pure TCC (95) 21 Ref.
TCC with SCC (5) 3 1.6 (0.76-2.7) .20
Operation
Yes (94) 22 Ref.
No (6) 2 1.6 (0.63-2.9) .28
Chemotherapy/Radiotherapy
None (52) 8 Ref.
Chemotherapy (24) 6 1.1 (0.63-1.9) .71
Radiotherapy (4) 1 1.2 (0.28-2.9) .74
Both (16) 7 1.7 (0.98-2.8) .058
XPC (Lys939Gln, A/C)
Lys/Lys (27) 12 Ref. Ref.
Lys/Gln (46) 9 0.63 (0.40-0.98) .038
Gln/Gln (18) 1 0.32 (0.076-0.74) .0039
Lys/Gln + Gln/Gln (64) 10 0.55 (0.35-0.84) .0058 0.37 (0.19-0.65) .0005
Lys/Lys + Lys/Gln (73) 21 Ref.
Gln/Gln (18) 1 0.38 (0.090-0.84) .012
XPD (Lys751Gln, A/C)*
Lys/Lys (93) 22 Ref.
Lys/Gln + Gln/Gln (3) 0 Not calculated .13
XPG (Asp1104His, G/C)
Asp/Asp (19) 4 Ref.
Asp/His (41) 15 1.3 (0.79-2.5) .31
His/His (34) 4 0.74 (0.36-1.5) .41
Asp/His + His/His (75) 19 1.1 (0.67-2.0) .73
Asp/Asp + Asp/His (60) 19 Ref.
His/His (34) 4 0.62 (0.33-1.0) .054
XRCC1 (Arg399Gln, G/A)*
Arg/Arg (50) 14 Ref.
Arg/Gln + Gln/Gln (46) 9 0.81 (0.52-1.2) .32
XRCC3 (Thr241Met, C/T)*
Thr/Thr (79) 20 Ref.
Thr/Met + Met/Met (15) 2 0.61 (0.24-1.1) .13
Total variant alleles in DNA repair genes
≤ 3 (73) 22 Ref. Ref.
> 3 (27) 2 0.43 (0.17-0.80) .0048 0.31 (0.073-0.70) .0016
Total variant alleles in NER genes†
≤ 2 (70) 23 Ref. Ref.
> 2 (29) 1 0.32 (0.076-0.70) .0015 0.39 (0.090-0.87) .018
Bold font indicates statistical significance.
UUT-TCC indicates upper urinary tract transitional cell carcinoma; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; NER, nucleotide excision repair; Ref., Reference.
*For those polymorphisms with few homozygous variant alleles, only the combined results of the heterozygous and homozygous variant alleles were shown.
†NER genes included XPC, XPD, and XPG.
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all DNA repair genes studied and those with more than two total
variant alleles in NER genes had significantly improved survival.
The wild-type genotypes conferring suboptimal DNA repair in the
tumor might lead to the accumulation of multiple genetic changes
and to biologically more aggressive UUT-TCC. It has been shown
that the wild-type genotypes of the XPC, XPD, XPG, and XRCC1
genes are associated with decreased DNA repair capacity [8,10–
12], and these results are in accord with our findings.
On the contrary, another study showed that genetic polymor-
phisms in NER pathway could explain only a small amount of the
variability in DNA repair capacity using an assay measuring the re-
moval of in vitro–induced benzo[a]pyrene diolepoxide–DNA ad-
ducts in lymphoblastoid cells in sisters discordant for breast cancer
from the New York Registry [35]. Although the accurate cause for
the discrepancy in the findings between this and our studies is un-
certain, it might be due to the differences in ethnic backgrounds,
methods for DNA repair capacity assay, or cancer types.
DNA repair gene polymorphisms potentially influenced malignant
phenotypes of UUT-TCC in our present study, although they were
germline variations not somatic mutations in tumor cells. Loktionov
[36] demonstrated that both cancer initiation risk and later neoplastic
events (tumor growth, invasion, metastatic spread, response to thera-
peutic interventions, and finally, survival) are strongly affected by factors
that are predetermined by the individual’s genetic background. Hunter
[37] also stated that recent evidence implies a significant role of germ-
line polymorphisms in cancer progression. Germline polymorphisms
may play an important role in cancer progression because cancer de-
velopment and progression strongly depend on altered interactions
between malignant cells and their normal neighbors [27].
Because the population of our UUT-TCC patients had heteroge-
neity with multiple stages and therapies, we included these factors as
categorical variables in multivariate analyses for survival using Cox
proportional hazard regression models. In these analyses, some
DNA repair genotypes were found to be independently associated
with survival beyond tumor stage and grade, whereas therapeutic mo-
dalities did not significantly affect the survival. If our findings that
the modulated DNA repair capacity caused by the DNA repair geno-
types might have a significant impact on the survival of UUT-TCC
patients are confirmed in functional and larger studies, modification
of the DNA repair enzyme level or DNA repair pathway signaling
might be a novel therapeutic target for UUT-TCC.
In the case–control study, no significant associations were observed
between DNA repair genotypes and individual risk for UUT-TCC.
We have therefore concluded this study to be negative, with respect
to UUT-TCC susceptibility. However, the sample size was limited to
detect these associations, and larger studies are needed, including the
analysis of smoking status both in cases and controls, such as some
other types of cancer [14,15,38,39].
Figure 2. Kaplan-Meier disease-specific survival curves for patients with UUT-TCC by DNA repair genotypes (log-rank tests). (A) Lys/Gln +
Gln/Gln versus Lys/Lys of XPC; P = .0032. (B) His/His versus Asp/Asp + Asp/His of XPG; P = .069. (C) Total variant alleles in all DNA repair
genes studied: > 3 versus ≤ 3; P = .012. (D) Total variant alleles in NER genes (XPC, XPD, and XPG): > 2 versus ≤ 2; P = .0066.
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Concerning bladder cancer, there have been several reports on the
significant associations between DNA repair genotypes and risk or
progression [7,14–20,38]. Sanyal et al. [20] showed that bladder can-
cer patients that were simultaneous carriers of variant alleles at the
XPD (Lys751Gln) and XPC (Lys939Gln) polymorphisms were at
lower risk of death than other patients (P = .001). This result is partly
compatible with our findings in UUT-TCC patients. Cigarette
smoking and exposure to certain industrial dyes or solvents are asso-
ciated with an increased risk of UUT-TCC, similar to bladder TCC
[21]. However, phenacetin-containing analgesics and Balkan ne-
phropathy are stronger risk factors for UUT-TCC than for bladder
TCC [40,41]. In addition, UUT-TCC is associated with hereditary
nonpolyposis colorectal cancer (HNPCC), because UUT-TCC oc-
curs at a higher rate in patients with HNPCC [42,43]. Microsatellite
instability, which is a well-established feature of HNPCC [44], ap-
peared to be at a high level in patients with UUT-TCC, whereas it is
a rare event in those with bladder TCC [43,45,46]. Thus, there are a
few, but substantial, differences in the etiology and genetic alterations
between UUT and bladder TCCs. Comparing the associations be-
tween DNA repair polymorphisms and cancer risk and prognosis
in patients with UUT-TCC, with those in patients with bladder
TCC, might provide a better understanding of the mechanism un-
derlying the development and progression of UUT-TCC.
In conclusion, our study provides evidence that some DNA repair
genotypes are independently associated with survival and may pre-
operatively be valuable as prognostic factors for UUT-TCC beyond
tumor stage and grade, possibly due to altered DNA repair capacity
caused by these polymorphisms. However, our results with a limited
sample size allow only preliminary conclusions, and larger studies are
needed to confirm the associations between DNA repair gene poly-
morphisms and the clinical outcomes of patients with UUT-TCC.
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